AstraZeneca PLC (NASDAQ: AZN) is -3.33% lower on its value in year-to-date trading and has touched a low of $53.63 and a high of $71.70 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AZN stock was last observed hovering at around $56.44 in the last trading session, with the day’s loss setting it -0.13% off its average median price target of $71.97 for the next 12 months. It is also 44.45% off the consensus price target high of $101.36 offered by 28 analysts, but current levels are 0.46% higher than the price target low of $56.57 for the same period.
Currently trading at $56.31, the stock is -8.08% and -12.36% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 7.52 million and changing -0.23% at the moment leaves the stock -10.16% off its SMA200. AZN registered -4.14% loss for a year compared to 6-month gain of -12.45%.
The stock witnessed a -15.23% loss in the last 1 month and extending the period to 3 months gives it a -12.63%, and is -3.15% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.60% over the week and 1.87% over the month.
AstraZeneca PLC (AZN) has around 83100 employees, a market worth around $175.63B and $44.04B in sales. Fwd P/E is 15.47. Profit margin for the company is -2.80%. Distance from 52-week low is 5.00% and -21.46% from its 52-week high. The company has generated returns on investments over the last 12 months (2.00%).
AstraZeneca PLC (AZN) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for AstraZeneca PLC (AZN) is a “Buy”. 28 analysts offering their recommendations for the stock have an average rating of 1.70, where 5 rate it as a Hold and 3 think it is a “Overweight”. 20 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
AstraZeneca PLC is expected to release its quarterly report on 11/10/2022.The EPS is expected to shrink by -96.80% this year
AstraZeneca PLC (AZN) Top Institutional Holders
The shares outstanding are 3.10B, and float is at 2.99B with Short Float at 0.30%.
AstraZeneca PLC (AZN): Who are the competitors?
The company’s main competitors (and peers) include Eli Lilly and Company (LLY) that is trading 36.17% up over the past 12 months and Biogen Inc. (BIIB) that is -30.66% lower over the same period. Johnson & Johnson (JNJ) is 1.37% up on the 1-year trading charts.